Safety and Efficacy of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-31

Study Completion Date

2018-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is aimed to assess the anti-infective efficacy of D-PLEX over a period of 3 months post operation as well as the safety over a period of 6 months, by preventing sternal infection post cardiac surgery in patients above the age of 18, including high risk patients for infection. This study is a 2 parts study: part 1 is a single arm, part 2 is randomized controlled study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Peri-operative Risk Factors for Surgery Site Infection in Cardiac Surgery

NCT02392936

Surgical Site Infection

UNKNOWN

Mediastinitis and Staphylococcus Aureus

NCT03262558

Surgery, Cardiac Infection

COMPLETED

Management Practices and the Risk of Infection Following Cardiac Surgery

NCT01089712

Cardiac Surgery Infection, Postoperative Wound Postoperative Wound Infection +2 more

COMPLETED

Surgical Management of Blood in the Pericardial Sac After Penetrating Trauma

NCT00823160

Heart Injuries

COMPLETED NA

Incidence and Outcome of Perioperative Myocardial Injury After Non-cardiac Surgery

NCT02573532

Perioperative Myocardial Injury

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

D-PLEX is a new formulation of extended controlled release Doxycycline.

Subjects who meet the eligibility criteria and provide signed informed consent, will be enrolled into the study and will be treated with D-PLEX concomitantly with standard of care.

D-PLEX will be administered as a single application during a cardiac surgery (index procedure) immediately prior to sternal closure, as an adjunct to the standard care.

The study will assess the efficacy and safety of the controlled release antibiotic (doxycycline) by the reduction in the number of sternal infections observed during the treatment period in any subject above the age of 18 years, including patients with high risk for infection.

Additional follow up for prolonged safety assessments only, will be done as follows until 24 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Wound Infection Superficial Incisional Postoperative Wound Infection Deep Incisional Surgical Site

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Phase Ib/II, Prospective, Multicenter, Two part study; Part 1 Open Label, Single arm \& Part 2 Randomized, Single-blinded, D-PLEX Concomitantly with Standard Of Care vs. Standard of Care alone.

Study population include subjects above the age of 18 years, that undergoing cardiac surgery through mid-sternotomy, including patients with high risk of infection, such as diabetes (Insulin and/or non-insulin dependent), patients with Peripheral Vascular Disease (PVD), Chronic Obstructive Pulmonary Disease (COPD), heavy smokers, Bilateral Mammary artery harvesting, and subjects administered chronic steroid treatment.

Subjects who meet the eligibility criteria and provide signed informed consent, will be enrolled into the study and will be treated with D-PLEX concomitantly with standard of care (part 1) or randomized 2:1 to D-PLEX concomitantly with standard of care vs. standard of care only (part 2).

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment arm

Subjects who meet the eligibility criteria and provide signed informed consent, will undergo open heart surgery according to standard of care with treatment by D-PLEX.

Group Type EXPERIMENTAL

D-PLEX

Intervention Type DRUG

D-PLEX will be administered as a single application during the open heart surgery (index procedure) immediately prior to sternal closure, as an adjunct to the standard care.

Open heart surgery

Intervention Type PROCEDURE

Subject will undergo open heart surgery according to standard of care

Control arm

Subjects who meet the eligibility criteria and provide signed informed consent, will undergo open heart surgery according to standard of care.

Group Type OTHER

Open heart surgery

Intervention Type PROCEDURE

Subject will undergo open heart surgery according to standard of care

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

D-PLEX

D-PLEX will be administered as a single application during the open heart surgery (index procedure) immediately prior to sternal closure, as an adjunct to the standard care.

Intervention Type DRUG

Open heart surgery

Subject will undergo open heart surgery according to standard of care

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SOC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or non-pregnant female above 18 years old
2. Female of childbearing potential should have a negative serum pregnancy test prior to index procedure.

Note: All female of childbearing potential must agree to use a highly effective method of contraception (such as double barrier, oral or parenteral hormonal, intrauterine device and spermicide) consistently and correctly for the duration of the study.
3. Subjects undergoing elective or urgent cardiac surgery, who are preoperative stable hemodynamically.
4. Subjects with (20≤BMI≤40)
5. Subjects who sign a written informed consent.

Exclusion Criteria

1. Received any investigational drug within 30 days of start of study or within 5½ half-lives (pharmacokinetic or pharmacodynamics) prior to enrollment (whichever is longer).
2. Are ineligible to receive treatment with:

* Any preoperative active significant infection
* Antibiotic sensitivity to Doxycycline and/or tetracycline family of drugs
* Known allergies to more than 3 substances.(Patients should fill the allergy questioners during the enrolment process)
* History of allergic/hypersensitivity reaction to any substance having required hospitalization and/or treatment with intra-venous steroids/epinephrine or in the opinion of the investigator the patient is at high risk of developing severe allergic / hypersensitivity reactions.
* History of uncontrolled Asthma (GINA III-IV)
* History of chronic urticaria
3. Pregnant or breastfeeding women.
4. Subjects who have taken oral or IV doxycycline during the last 4 weeks prior to screening.
5. Subjects who undergo cardiac/open chest surgeries, which are classified as emergency.
6. Immunocompromised subjects from any reason, at screening.
7. Subjects that undergone TIA/ CVA within the last 3 months prior to enrollment.
8. Subjects that previously underwent any cardiac surgery through mid-sternum.
9. In the opinion of investigator, subject is not eligible to participate in the study due to a cognitive status, medical condition or medication status (other than items listed above)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No